Anthony J. Olszanski, RPh, MD, and Michael A. Davies, MD, PhD, on the COMBI-d Study on Cutaneous Melanoma
2016 ASCO Annual MeetingAnthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).
Related Videos
Luis G. Paz-Ares, MD, PhD, on NSCLC: Results From the SQUIRE Trial
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses study findings on adding necitumumab to gemcitabine and cisplatin chemotherapy in the first-line t...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings ...
James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma
James Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Ab...
Julie R. Park, MD, on Neuroblastoma: Results of a Children’s Oncology Group Study
Julie R. Park, MD, of Seattle Children’s Hospital, discusses findings from this phase III trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cel...
Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant...
